Dr. Bray Links

Monday, November 27, 2017

Flavocoxid for OA Tied to Life-Threatening Health Problems

The US Food and Drug Administration (FDA) is investigating serious adverse events involving flavocoxid (Limbrel, Primus Pharmaceuticals), a prescription product in capsule form that is marketed as a medical food for the management of metabolic processes associated with osteoarthritis.

"While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis," the FDA said in a safety communication November 21.

The FDA said it has received 194 reports of adverse event involving flavocoxid. In 30 of those cases, there was sufficient information to determine that flavocoxid was likely associated with these adverse events, the FDA said.

Flavocoxid is available in capsule form in two doses: 250 mg and 500 mg. The labeling states that the products contain two types of flavonoids: baicalin (from Scutellaria baicalensis) and catechin (from Acacia catechu). The products also contain zinc. The product labels say flavocoxid is intended for the managaement of the metabolic processes associated with osteoarthritis.


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.